Project Grant R01HL181161
Award Date 8/15/25
Completion Date 5/31/30
Dollars Obligated $403K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Heart Lung and Blood Institute (NHLBI) awarded a $129,021 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University to develop injectable liposome nanoparticle crosslinked (LINC) hydrogels for sustained delivery of protein therapeutics to treat myocardial infarction (MI). The research aims to synthesize a library of HA-LINC hydrogels, optimize liposome stabilization, and evaluate the gels' viscoelastic properties,...
- This Project Grant award of $1,290,338 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research conducted by Jaan Biotherapeutics, Inc. to develop a gene therapy treatment for heart muscle regeneration after myocardial infarction. The research aims to inhibit four specific microRNAs that regulate cardiomyocyte dedifferentiation, proliferation, and redifferentiation, with the goal of stimulating endogenous heart muscle regeneration and...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $769,789 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to The Leland Stanford Junior University (Stanford University). This 4-year grant, effective June 1, 2025, supports the development of a novel injectable, biodegradable hydrogel to provide sustained delivery of the protein therapy neuregulin-1 (NRG1) for the treatment of myocardial infarction (heart attack). The project aims to...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
- The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $694,252.00 to Cedars-Sinai Medical Center in California to investigate the mechanisms of cardioprotective Y RNA signaling in macrophages. The goal is to better understand how a small non-coding RNA called YREX3 can enhance the ability of macrophages to clear dead cells and promote cardiac tissue healing after a myocardial...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $729,703 to The Trustees of Columbia University in the City of New York to develop a technology called "NanoVials" to sort and enrich mesenchymal stem cells (MSCs) based on their extracellular vesicle (EV) secretion levels. The goal is to optimize stem cell therapies for ischemic diseases like myocardial infarction by identifying and utilizing MSCs with...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $388,036 to Laborecom Therapeutics Inc. to develop a novel therapeutic peptide to reduce myocardial reperfusion injury. The goal is to optimize the peptide's stability, permeability, and activity, and then evaluate its ability to improve heart function and limit infarct size in a mouse model of myocardial infarction. Successful completion of this Phase I SBIR...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $542,094 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Kentucky Research Foundation. The grant, awarded on March 18, 2025, aims to advance the preclinical development of a liposomal formulation of the antibiotic azithromycin (L-AZM) for the treatment of cardiac inflammation and remodeling following myocardial infarction. The key objectives are to determine the optimal dose,...